{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T03:00:33Z","timestamp":1763348433136,"version":"build-2065373602"},"reference-count":22,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.clml.2022.04.022","type":"journal-article","created":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T22:18:38Z","timestamp":1651011518000},"page":"e836-e843","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Time to First Subsequent Salvage Therapy in Patients With Relapsed\/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE Trial"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9331-5145","authenticated-orcid":false,"given":"Matthias","family":"Stelljes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjali S","family":"Advani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel J","family":"DeAngelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Neuhof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Vandendries","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-3307","authenticated-orcid":false,"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.04.022_bib0001","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/ajh.25561","article-title":"Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL)","volume":"94","author":"Al-Sawaf","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2022.04.022_bib0002","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.clml.2019.08.004","article-title":"Comparison of time to next treatment, health care resource utilization, and costs in patients with chronic lymphocytic leukemia initiated on front-line ibrutinib or chemoimmunotherapy","volume":"19","author":"Emond","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2022.04.022_bib0003","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1182\/blood-2007-07-099432","article-title":"Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia","volume":"112","author":"Kujawski","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.022_bib0004","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/ajh.23737","article-title":"Chemoimmunotherapy for relapsed\/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells","volume":"89","author":"Zent","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2022.04.022_bib0005","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1200\/JCO.2012.45.6400","article-title":"90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial","volume":"31","author":"Morschhauser","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.04.022_bib0006","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1182\/blood-2018-10-879643","article-title":"Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy","volume":"134","author":"Zucca","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.04.022_bib0007","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/annonc\/mdn656","article-title":"Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study","volume":"20","author":"Goy","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2022.04.022_bib0008","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.3324\/haematol.2016.144311","article-title":"International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed\/refractory acute lymphoblastic leukemia","volume":"101","author":"Gokbuget","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.04.022_bib0009","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1182\/blood-2003-07-2466","article-title":"Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies","volume":"103","author":"DiJoseph","year":"2004","journal-title":"Blood"},{"issue":"2 Pt A","key":"10.1016\/j.clml.2022.04.022_bib0010","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.molimm.2014.09.014","article-title":"Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies","volume":"67","author":"Shor","year":"2015","journal-title":"Mol Immunol"},{"key":"10.1016\/j.clml.2022.04.022_bib0011","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study","volume":"125","author":"Kantarjian","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2022.04.022_bib0012","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.04.022_bib0013","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1080\/10428194.2020.1751839","article-title":"Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed\/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database","volume":"61","author":"Jabbour","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.04.022_bib0014","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2022.04.022_bib0015","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2022.04.022_bib0016","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/cncr.33340","article-title":"Sequencing of novel agents in relapsed\/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed\/refractory acute lymphoblastic leukemia","volume":"127","author":"Badar","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2022.04.022_bib0017","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00277-020-04227-8","article-title":"Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia","volume":"100","author":"Wullenkord","year":"2021","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2022.04.022_bib0018","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/cncr.30622","article-title":"Meaningful endpoints for therapies approved for hematologic malignancies","volume":"123","author":"Smith","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2022.04.022_bib0019","doi-asserted-by":"crossref","first-page":"5959","DOI":"10.1002\/cam4.2480","article-title":"Burden of hospitalization in acute lymphoblastic leukemia patients treated with inotuzumab ozogamicin versus standard chemotherapy treatment","volume":"8","author":"Marks","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2022.04.022_bib0020","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1182\/blood.V126.23.681.681","article-title":"Durable remissions in children with relapsed\/refractory ALL treated with T cells engineered with a CD19-targeted chimeric antigen receptor (CTL019)","volume":"126","author":"Grupp","year":"2015","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.clml.2022.04.022_bib0021","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1200\/JCO.2016.34.15_suppl.3011","article-title":"Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed\/refractory ALL","volume":"34","author":"Maude","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.04.022_bib0022","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"Gokbuget","year":"2018","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022001379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265022001379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:40:00Z","timestamp":1761871200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265022001379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S2152265022001379"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.04.022","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Time to First Subsequent Salvage Therapy in Patients With Relapsed\/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.04.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}